MAIA Biotechnology Files 8-K

Ticker: MAIA · Form: 8-K · Filed: Jun 24, 2025 · CIK: 1878313

Maia Biotechnology, INC. 8-K Filing Summary
FieldDetail
CompanyMaia Biotechnology, INC. (MAIA)
Form Type8-K
Filed DateJun 24, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-k

TL;DR

MAIA Bio filed an 8-K, but it's light on details for now.

AI Summary

MAIA Biotechnology, Inc. filed an 8-K on June 24, 2025, reporting other events and financial statements. The filing does not contain specific details about the nature of these events or any financial figures.

Why It Matters

This filing indicates that MAIA Biotechnology, Inc. has made a regulatory submission, but the lack of specific details prevents an immediate assessment of its impact.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without disclosing specific material events, making it low risk.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by MAIA Biotechnology, Inc. in this 8-K?

The filing does not specify the nature of the 'Other Events' beyond listing it as an item information category.

What is the purpose of filing 'Financial Statements and Exhibits' as an item in this 8-K?

The filing lists 'Financial Statements and Exhibits' as an item, but does not provide the actual financial statements or detail which exhibits are included.

When was the earliest event reported in this 8-K filing?

The earliest event reported is dated June 24, 2025.

Where is MAIA Biotechnology, Inc. headquartered?

MAIA Biotechnology, Inc.'s principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.

What is the SEC file number for MAIA Biotechnology, Inc.?

The SEC file number for MAIA Biotechnology, Inc. is 001-41455.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 24, 2025 regarding MAIA Biotechnology, Inc. (MAIA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing